BUZZ-Aadi Bioscience gains on licensing agreement for cancer drugs

Reuters12-20 19:20
BUZZ-Aadi Bioscience gains on licensing agreement for cancer drugs

** Shares of Aadi Bioscience AADI.O rise about 40% to $3.25 in premarket trading

** AADI says that it entered into an agreement with China-based biotech firms WuXi Biologics 2269.HK and HANGZHOU DAC to develop and potentially sell three experimental antibody-drug conjugates (ADCs) treatments

** AADI will pay $44 mln upfront and $805 mln in milestone payments under the agreement to the firms

** Separately, company is selling its FDA-approved cancer treatment, Fyarro, to KAKEN Pharmaceutical 4521.T for $100 mln

** AADI expected to raise about $100 mln through private investment in public equity (PIPE) financing

** Proceeds from the sale of the cancer drug and PIPE financing are expected to fund company's operations into late 2028 - AADI

** As of last close, stock has risen about 15% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment